- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Vitens, Leading Dutch Utility, To Lease BioSentry Water Monitoring System from Company's Distributor
JMAR Technologies, Inc. (OTCBB:JMAR) announced today that it has received a purchase order from Interline Systems BV, JMAR's distributor who will install and lease the BioSentry™ Water Monitoring System to Vitens, a leading Dutch water utility that serves approximately 5.4 million consumers. The order comes just six weeks after the Company received an order from Yorkshire Water Services Ltd., a leading water utility in England. This test program marks the second water utility application for BioSentry in Europe. Vitens will lease the BioSentry System for an evaluation period of six months. Upon successful completion of the test period, it will have the option to purchase the unit for permanent installation.
The initial installation at Vitens will determine the effectiveness of the BioSentry in detecting pathogenic bacteria such as E-Coli and Legionella that can contaminate water distribution systems. BioSentry is part of a Vitens' initiative to develop a complete water security monitoring system inclusive of chemical and biological agents.
"BioSentry is a key component of water contamination monitoring as it's the only biological detection system that provides on-line, real-time results," said Wouter van Delft, project leader of Vitens. "Throughout Europe, waterborne pathogen events are becoming more and more prevalent and BioSentry can help to identify the presence and behavior of microorganisms in the water treatment and distribution processes."
"We are excited to receive another order from a major European water utility so quickly after receiving the initial purchase order from Yorkshire Water," stated Neil Beer, JMAR's President and CEO. JMAR has BioSentry Systems installed in the beverage quality assurance, water utility operations, cruise ship water monitoring, and homeland security markets. In addition, the system is being tested by the U.S. Environmental Protection Agency for homeland security applications.
About JMAR Technologies
JMAR Technologies, Inc. is a leading innovator in the development of laser-based technology and x-ray processes for nano-scale imaging, analysis and fabrication. The Company is leveraging more than a decade of laser and photonics research to develop a portfolio of products with commercial applications in rapidly growing industries, while continuing to carry out research and development for the U.S. Government.
JMAR's leading commercial product, BioSentry(TM), is a contamination warning system for waterborne microorganisms. BioSentry uses laser-based, multi-angle light scattering technology to provide continuous, on-line, real-time monitoring for harmful microorganisms. BioSentry is targeted toward a number of applications across multiple markets, including homeland security, the cruise ship and beverage industries, pharmaceutical companies, and municipal water utilities.
JMAR's pursuit of leading edge products targets nanotechnology, bioscience and the semiconductor industries with its BriteLight(TM) laser, a stand-alone product as well as the x-ray light source in nanolithography systems; the X-ray Microscope for 3D visualization of single cells and polymers; and the X-ray NanoProbe for enabling nano-scale interaction, analysis and materials modification. In addition, JMAR employs key strategic alliances for the production of a hazardous materials chemical sensor, and the prototyping and production of a nanoparticle ultra-thin coating system.
This news release contains certain “forward-looking statements.” Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company’s control. Actual results could differ materially from these forward-looking statements as a result of a number of factors, including the risk that the transition of the trading or quotation of our shares of common stock to the OTC Bulletin Board or to the “Pink Sheets” may have an adverse effect on the price or liquidity of our shares of common stock, including a possible decline in the number of market makers who are willing to make a market in our stock, and our ability to engage in certain financing transactions on terms as favorable as when the Company’s shares were traded on The Nasdaq Stock Market, the performance validation tests of the BioSentry Beta units are not successfully completed due to unforeseen issues with the installation and operation of the units outside of the controlled environment of JMAR’s facility, delays in completion of the X-ray Microscope and X-ray Nano Probe prototypes and transition to production units, the failure of the technology to perform as predicted, competition from alternative technologies, uncertainties as to the size of the markets, cost and margins for JMAR’s products, failure to obtain market acceptance, current or future government regulations affecting the use of JMAR’s products, the lack of availability of critical components, the degree of protection from future patents, other risks associated with the development or acquisition of new products or technologies and those risks detailed in the Company’s Form 10-K for the year ended December 31, 2005 and Form 10-Q for the quarter ended September 30, 2006 filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. JMAR Technologies, Inc. does not assume any duty to publicly update or revise the material contained herein.
For more information, please click here
JMAR Technologies, Inc.
Kathi Kirchmeier, 858-946-6800
Marketing Communications Manager
Andrew Hellman, 212-732-4300
Copyright © Business WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
The molecular mechanism that blocks membrane receptors has been identified: The work in which the Ikerbasque researcher of the Biofisika Institute Xabier Contreras has participated has been published in the journal Cell October 27th, 2016
Chad Mirkin receives nanotechnology prize in Russia October 26th, 2016
Imaging where cancer drugs go in the body could improve treatment October 26th, 2016
Oxford Instruments systems now facilitate water purification technology September 27th, 2016
Atomic scale pipes available on demand and by design September 9th, 2016
Revolutionary Composite Gas Transition Seal October 4th, 2016
FEI Celebrates Shipment of 1,000th Helios DualBeam System: FEI’s Helios Family has lead the DualBeam technology race and is widely used across the semiconductor, materials science, life sciences and oil & gas industries August 31st, 2016